Document is current

Article History

Received: 14 July 2021

Accepted: 18 March 2022

First Online: 1 April 2022

Declarations

:

: Before recruitment of subjects, all study documents were submitted and approved by Copernicus Group Independent Review Board®, approval number Clinical Outcomes Solutions (COS)1-17-209. Interviews were conducted after the participant had signed and returned the informed consent document to COS.

: Not applicable.

: The datasets generated and/or analyzed during the current study are not publicly available due to the sensitive nature of the questions asked in this study but are available from the corresponding author on reasonable request.

: MCD has received consultant fees or research support from Janssen, AbbVie, Roche, UCB, Pfizer, Takeda, Arena, Prometheus, Celgene, Lilly. PMI has received honoraria for acting in an advisory capacity from AbbVie, Celgene, Genentech, Gilead, Hospira, Janssen, Lilly, MSD, Pfizer, Pharmacosmos, Prometheus, Samsung Bioepis, Sandoz, Takeda, Topivert, VH2, Vifor, and Warner Chilcott; received speaker fees from AbbVie, Falk Pharma, Ferring, Janssen, MSD, Pfizer, Sandoz, Shire, Takeda, Tillotts, and Warner Chilcott; and received research funding from MSD, Pfizer, and Takeda. RP has received consultant and/or lecture fees from AbbVie, Amgen, AstraZeneca, Axcan Pharma (now Aptalis), Biogen Idec, Bristol Myers Squibb, Centocor, ChemoCentryx, Eisai Medical Research Inc., Elan Pharmaceuticals, Ferring, Genentech, GlaxoSmithKline, Janssen, Merck Sharp & Dohme, Millennium Pharmaceuticals (now Takeda Oncology), Ocera Therapeutics Inc., Otsuka America Pharmaceutical, Pfizer, Shire Pharmaceuticals, Prometheus Laboratories, Schering-Plough Corporation, Synta Pharmaceuticals Corp., Teva, UCB Pharma, and Warner Chilcott. ANN, APB, VA, and MS are employees and stockholders at Eli Lilly and Company. ST has received grants/research support from AbbVie, Buhlmann, Celgene, International Organization for the study of Inflammatory Bowel Diseases, Janssen, Lilly, Takeda, UCB, Vifor, and Norman Collisson Foundation; has received consulting fees from Abacus, AbbVie, Actial, ai4gi, Alcimed, Allergan, Amgen, Arena, Asahi, Astellas, Atlantic, AstraZeneca, Barco, Biocare, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Buhlmann, Calcico, Celgene, Celsius, Cellerix, Cerimon, ChemoCentryx, Cisbio, Coronado, Cosmo, Ducentis, Dynavax, Elan, Enterome, Falk, Ferring, FPRT Bio, Giuliani SpA, Genentech, Genzyme, Glenmark, Grunenthal, GlaxoSmithKline, GW Pharmaceuticals, Immunocore, Immunometabolism, Indigo, Janssen, Lexicon, Lilly, Medarex, Merck, MSD, Netbiotix, Neovacs, Novartis, Novo Nordisk, NPS Pharmaceuticals, Ocera, Ptima, Otsuka, Palau, Pentax, Pfizer, Philips, Procter & Gamble, Pronota, Proximagen, Resolute, Receptos, Robarts, Roche, Sandoz, Santarus, Sensyne, Shire, Sigmoid Pharma, SynDermix, Synthon, Takeda, Theravance, TiGenix, Tillotts, Topivert, TxCell, UCB, Vertex, VHsquared, Vifor, Warner Chilcott, and Zeria; and has received speaker fees from AbbVie, Amgen, Biogen, Falk, Ferring, GlaxoSmithKline, Janssen, Shire, Takeda, and Zeria.